Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
What Doximity (NYSE: DOCS) CFO resignation means for governance, capital allocation, and investor confidence
Read More Pharma Industry News Vyriad and Merck launch Phase 1 trial for innovative immuno-oncology drug combination Vyriad, a US-based biotech company, has partnered with Germany’s Merck to initiate a Phase 1 clinical trial targeting… bypharmanewsdailyJuly 18, 2018
